Labroots

Gilenya: First Treatment for Pediatric MS

“For the first time, we have an FDA-approved treatment specifically for children and adolescents with multiple sclerosis,” explains Billy Dunn, M.D., director of the Division of Neurology Products in ...
FiercePharma

Novartis announces presentation of data at AAN showing Gilenya® slowed the rate of brain volume loss in MS patients

MS patients have accelerated brain volume loss (up to 3-5 times faster than people without MS), which is associated with physical & cognitive loss of function Data at AAN showed significantly more ...
FiercePharma

The Majority of Surveyed Neurologists in the EU5 Expect Both Gilenya and Oral Cladribine to Secure Initial European Approval for

The Anticipated High Cost of Gilenya and Oral Cladribine Will Not Be a Significant Hurdle to Their Reimbursement in Europe, According to a New Report from Decision Resources BURLINGTON, Mass., Dec. 15 ...
Pharmabiz

Novartis announces positivedata from phase IV MS-MRIUS study on Gilenya

Novartis has announced data from the phase IV Multiple Sclerosis and clinical outcome and MRI in the US (MS-MRIUS) study, which confirmed the effectiveness of Gilenya (fingolimod) in the real-world ...
Business Insider

Benefitting From Expanded Access in Europe, Roche's Ocrevus is on Track to Displace Biogen's Tysabri in Neurologist Preference and Share Among Patients with Relapsing Forms of ...

EXTON, Pa., Oct. 7, 2019 /PRNewswire/ -- Expanded access to Merck KGaA's Mavenclad and Roche's Ocrevus in Europe has significantly shifted neurologists' reported disease-modifying therapy (DMT) ...
FierceBiotech

Critical Therapeutic Objectives Continue to go Unmet for the Treatment of Multiple Sclerosis Even with the Assimilation of

EXTON, Pa.--(BUSINESS WIRE)-- Trial and share of Novartis’ Gilenya, the first oral disease-modifying agent (DMA) for the treatment of multiple sclerosis (MS), to grow suggesting increasing acceptance ...
Business Wire

Multiple Sclerosis Patients in US Left Without Essential Patient Support Program Will Now Receive Equivalent Backing From Cycle Pharmaceuticals Following FDA’s Approval of ...

BOSTON--(BUSINESS WIRE)--Cycle Pharmaceuticals Ltd (Cycle) has today welcomed the news that multiple sclerosis (MS) patients in the US currently being treated with Gilenya, or generic fingolimod to ...
clinicaladvisor.com

Family Planning in MS: A Gap in Patient Knowledge

“Healthcare professionals (the neurologist and the MS nurse) represented the most frequently used and important sources of information about MS in general, but for the information related to the ...
The Motley Fool

Can These Repurposed Antibodies Reshape the Multiple Sclerosis Market?

A previous clinical failure from Roche and an approved leukemia therapy from Novartis are making waves. With these next-generation therapies doing so well, you might think MS is the last indication ...
Business Insider

Neurologists Anticipate Overall Expansion of the Fumarate Class Following the US Launch of Biogen's Vumerity for Treatment in Multiple Sclerosis, According to Spherix Global ...

EXTON, Pa., Dec. 10, 2019 /PRNewswire/ -- Biogen's Vumerity (diroximel fumarate), a monomethyl fumarate prodrug, was approved by the FDA on October 30 th for the treatment of relapsing forms of ...
MM&M

Pent-up demand stands to drive Tecfidera, docs say

The approval of Biogen Idec’s MS therapy Tecfidera follows months of breathless Wall Street hype, and it looks like doctors are psyched for the drug, too. In a MedLIVE PULSE survey conducted for MM&M ...
Forbes

Rituxan Outperforms A Half-Dozen Multiple Sclerosis Therapies In Study

In a study of how people newly diagnosed with multiple sclerosis fared on the first therapy they tried, a drug that isn’t even approved for the disease came out on top. Rituximab, sold by Roche as ...